Citations

Clear

390 citation(s) found for "Loftus, E".

S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
Pangan, Aileen L., Greenbloom, Susan, D’Haens, Geert , Sandborn, William J. , Reinisch, Walter , Sanchez-Gonzalez, Yuri, Xian, Wangang, Liu, Jian-Zhong , Weinreich, Michael , Vermeire, Séverine , Danese, Silvio , Zhou, Wen , Panés, Julián , Juillerat, Pascal , Lindsay, James Oliver , Loftus, Edward V. , Reinisch, Walter , Huang, Bidan , Panaccione, Remo

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S357-S357

10.14309/01.ajg.0000776616.76910.14 Get It

S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study
Hoops, Timothy, Izanec, James , Ding, Zhijie , Muser, Erik, Gasink, Christopher , Sandborn, William J. , Loftus, Edward V. , Danese, Silvio , Panaccione, Remo , Ma, Tony Xuyen , Irving, Peter Miles , Allez, Matthieu

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S355-S357

10.14309/01.ajg.0000776612.28121.af Get It

S763 A Cohort Study of the Age of Menopause in Female Patients With and Without Inflammatory Bowel Disease
Moktan, Varun , Daoud, Nader , Tremaine, William J., Kane, Sunanda V. , Hochwald, Alexander , Hodge, David O. , Loftus, Edward V. , Faubion, Stephanie S. , Farraye, Francis A.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S352-S353

10.14309/01.ajg.0000776584.48281.9f Get It

S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study
Dubinsky, Marla C. , Ferrante, Marc , Song, Alexandra , Liao, Xiaomei, Berg, Sofie, Duan, W. Rachel, Wallace, Kori, Feagan, Brian G. , Panaccione, Remo , Schreiber, Stefan , Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Huang, Bidan

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S348-S348

10.14309/01.ajg.0000776548.94565.6c Get It

S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials
Louis, Édouard , Lee, Scott D. , Griffith, Jenny, Wallace, Kori, Berg, Sofie, Peyrin‐Biroulet, Laurent , Louis, Edouard , Ghosh, Subrata , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S338-S338

10.14309/01.ajg.0000776480.66336.75 Get It

S693 Impact of Prior Biologic Exposure on Patient Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study
Nguyen, Dianne, Pondel, Marc , Silver, Michael, Petersen, AnnKatrin, Wolf, Douglas C. , Sturm, Andreas , D’Haens, Geert , Sands, Bruce E , Petersen, AnnKatrin, Panaccione, Remo , Loftus, Edward V. , Colombel, Jean‐Frédéric

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S313-S314

10.14309/01.ajg.0000776304.52681.bf Get It

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
Sandborn, William J. , Lewis, James D. , Panés, Julián , Loftus, Edward V. , D’Haens, Geert , Yu, Zhuqing , Lacerda, Ana P. , Pangan, Aileen L., Feagan, Brian G. , Loftus, Edward V , Panes, Julian , Lewis, James D , Huang, Bidan

Mayo Clinic

Journal of Crohn's and Colitis | September 20, 2021 | Volume: 16 | Issue: 3 | Pages: 444-451

10.1093/ecco-jcc/jjab161 | PMID 34546360 Get It

Abstract Background and Aims Patient-reported outcomes are recommended endpoints in Crohn’s disease [CD] trials. The association between patient-reported general well-being relative to symptoms of diarrhoea and abdominal pain [AP] in patients with moderate to severe CD was explored. Methods Patients from three randomized, placebo-controlled, double-blind adalimumab or upadacitinib studies with average daily very soft/liquid stool frequency [SF] ≥4 and/or AP score ≥2 at baseline were included. Using electronic diaries, patients reported general well-being [seven-point Likert scale; 1 = worst; 7 = best] in item 10 of the Inflammatory Bowel Disease Questionnaire [IBDQ]. Changes in well-being and clinical outcomes of SF and AP from baseline to week 12 or 16, and the relationship between well-being and clinical outcomes were evaluated using cumulative distribution function and probability density function curves. Results In total, 858 patients with CD were included [adalimumab, n = 695; upadacitinib, n = 163]. Patients who achieved clinical remission [SF ≤2.8, AP score ≤1.0, neither worse than baseline] were more likely than those not in clinical remission to report IBDQ item 10 response in the 6–7 group category but not IBDQ categories ≤5. Higher IBDQ score for item 10 [6–7] was associated with lower SF and AP score. Greater point increases in IBDQ item 10 were associated with a greater percentage decrease in clinical parameters; a ≥25–30% decrease in SF or AP was associated with a ≥1-point improvement in IBDQ. Conclusions An association between improvements in patient-reported general well-being and clinical remission/response was observed using outcomes of SF and AP, supporting the clinical remission/response endpoint definitions used in clinical studies of CD. Clinical Trial Registrations [ClinicalTrials.gov]: NCT00077779 [CHARM]; NCT00348283 [EXTEND]; NCT02365649 [CELEST].
Vulvar Crohn's Disease: Clinical Features and Outcomes
Cho, Janice , Loftus, Edward V. , Bruining, David H. , Chedid, Victor , Faubion, William A. , Johnson, Amanda M. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Picco, Michael F., Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Cho, Janice M, Chedid, Victor G , Loftus, Edward V , Farraye, Francis A. , Kisiel, John B. , Malik, Talha A. , Coelho–Prabhu, Nayantara

Mayo Clinic

American Journal of Gastroenterology | September 9, 2021 | Volume: 116 | Issue: 11 | Pages: 2296-2299

10.14309/ajg.0000000000001502 | PMID 34732676 Get It

INTRODUCTION: Vulvar involvement is a rare complication of Crohn's disease (CD). The optimal treatment of vulvar CD is unknown. METHODS: We conducted a 25-year retrospective cohort study of vulvar CD from 3 referral centers. Clinical features and outcomes were studied. RESULTS: Fifty patients were identified. The most common vulvar symptoms were pain (74%), edema (60%), ulcerations (46%), nodules (36%), and abscess (34%). Medical management leading to symptomatic improvement varied, and 5 patients ultimately required surgery. DISCUSSION: Vulvar CD manifests with a broad spectrum of symptoms. Aggressive medical management was frequently effective, although surgery was required in 10% of cases.
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial
Vermeire, Séverine , D’Haens, Geert , Baert, Filip , Kobayashi, Taku, Loftus, Edward V. , Bhatia, Siddharth , Agboton, Christian , Rosario, Maria , Chen, Chunlin , Zhang, Wenwen , Kisfalvi, Krisztina, Sandborn, William J. , Kobayashi, Taku , Loftus, Edward V , Kobayashi, Taku , Vermeire, Séverine , Danese, Silvio

Mayo Clinic

Journal of Crohn's and Colitis | August 16, 2021 | Volume: 16 | Issue: 1 | Pages: 27-38

10.1093/ecco-jcc/jjab133 | PMID 34402887 Get It

Abstract Background and Aims To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn’s disease [CD]. Methods Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point decrease in CD Activity Index [CDAI] score from baseline) were randomised 2:1 to receive double-blind maintenance vedolizumab 108 mg SC or placebo every 2 weeks until Week 50. Assessments at Week 52 included clinical remission [primary endpoint; CDAI ≤150], enhanced clinical response [≥100-point decrease in CDAI from baseline], corticosteroid-free clinical remission among patients using a corticosteroid at baseline, clinical remission in anti-tumour necrosis factor [anti-TNF]-naïve patients, and safety. Results Following vedolizumab intravenous induction, 275 patients were randomised to vedolizumab SC and 135 to placebo maintenance. At Week 52, 48.0% of patients receiving vedolizumab SC versus 34.3% receiving placebo were in clinical remission [p = 0.008]. Enhanced clinical response at Week 52 was achieved by 52.0% versus 44.8% of patients receiving vedolizumab SC versus placebo, respectively [p = 0.167]. At Week 52, 45.3% and 18.2% of patients receiving vedolizumab SC and placebo, respectively, were in corticosteroid-free clinical remission, and 48.6% of anti-TNF-naïve patients receiving vedolizumab SC and 42.9% receiving placebo were in clinical remission. Injection site reaction was the only new safety finding observed for vedolizumab SC [2.9%]. Conclusions Vedolizumab SC is an effective and safe maintenance therapy in patients with CD who responded to two infusions of vedolizumab intravenous induction therapy.
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease
Cheifetz, Adam S. , Afif, Waqqas , Dubinsky, Marla C. , Loftus, Edward V. , Osterman, Mark T. , Saroufim, Ariana, Yarur, Andrés , Melmed, Gil , Papamichael, Konstantinos , Loftus, Edward V , Melmed, Gil Y , Yarur, Andres J , Abreu, María T. , Cross, Raymond K. , Siegel, Corey A

Mayo Clinic

American Journal of Gastroenterology | August 13, 2021 | Volume: 116 | Issue: 10 | Pages: 2014-2025

10.14309/ajg.0000000000001396 | PMID 34388143 Get It

Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to provide a consensus statement regarding the clinical utility of TDM for biologics in inflammatory bowel disease (IBD). A modified Delphi method was applied to develop consensus statements. A comprehensive literature review was performed regarding TDM of biologic therapies in IBD, and 45 statements were subsequently formulated on the potential application of TDM in IBD. The statements, along with literature, were then presented to a panel of 10 gastroenterologists with expertise in IBD and TDM who anonymously rated them on a scale of 1–10 (1 = strongly disagree and 10 = strongly agree). An expert consensus development meeting was held virtually to review, discuss, refine, and reformulate statements that did not meet criteria for agreement or that were ambiguous. During the meeting, additional statements were proposed. Panelists then confidentially revoted, and statements rated ≥7 by 80% or more of the participants were accepted. During the virtual meeting, 8 statements were reworded, 7 new statements were proposed, and 19 statements were rerated. Consensus was finally reached in 48/49 statements. The panel agreed that reactive TDM should be used for all biologics for both primary nonresponse and secondary loss of response. It was recommended that treatment discontinuation should not be considered for infliximab or adalimumab until a drug concentration of at least 10–15 μg/mL was achieved. Consensus was also achieved regarding the utility of proactive TDM for anti–tumor necrosis factor therapy. It was recommended to perform proactive TDM after induction and at least once during maintenance. Consensus was achieved in most cases regarding the utility of TDM of biologics in IBD, specifically for reactive and proactive TDM of anti–tumor necrosis factors.